Regeneron Pharmaceuticals has entered a strategic collaboration with Parabilis Medicines to develop Antibody-Helicon™ Conjugates (AHCs), a novel therapy class aimed at difficult-to-treat targets. Regeneron will invest $125 million upfront and potentially up to $2.2 billion in milestones, combining its antibody technology with Parabilis' Helicon peptide platform. This partnership aims to create new treatments by delivering Helicon peptides inside cells to modulate previously undruggable proteins. Regeneron will handle development, manufacturing, and commercialization of resulting therapies, advancing innovation across multiple disease areas.
Regeneron Pharmaceuticals' stock fell over 10% following the Phase 3 trial results for their melanoma treatment combining fianlimab and cemiplimab. The trial did not achieve statistical significance for the primary endpoint of progression-free surviv...
Regeneron's Phase 3 trial testing fianlimab (LAG-3 inhibitor) combined with cemiplimab (PD-1 inhibitor) as first-line treatment for unresectable or metastatic melanoma did not achieve statistical significance for its primary endpoint of improved prog...
At the 2026 Regeneron International Science and Engineering Fair, over $7 million in awards were given to more than 1,700 young STEM students from 67+ countries. Hikaru Kuribayashi, 17, won the top $100,000 prize for his simulation program predicting...
The 2026 Regeneron International Science and Engineering Fair awarded more than $7 million to over 1,700 young STEM finalists from 67+ countries. Hikaru Kuribayashi won the top $100,000 George D. Yancopoulos Innovator Award for creating a simulation ...
